Tokyo, Japan

Munemoto Itoh

This inventor holds 1 USPTO granted patent. Top assignee: Tobishi Pharmaceutical Co., Ltd.. Active years: 1979.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 1979

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Munemoto Itoh: Innovator in Antimalignant Agents

Introduction

Munemoto Itoh is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medical science, particularly in the development of antimalignant agents. His work has the potential to impact cancer treatment and improve patient outcomes.

Latest Patents

Itoh holds a patent for an "Agent for inhibiting tumor induced by leukemia virus." This innovative process involves cultivating Staphylococcus epidermidis STF in a liquid culture medium, followed by a series of purification steps to isolate the active ingredient that exhibits antimalignant activity. The patent outlines a comprehensive method that includes concentrating the culture solution, washing the precipitate, and further purifying the fraction through ion-exchange chromatography.

Career Highlights

Itoh is currently associated with Tobishi Pharmaceutical Co., Ltd., where he continues to advance his research in pharmaceuticals. His dedication to developing effective treatments for malignancies showcases his commitment to improving healthcare.

Collaborations

Throughout his career, Itoh has collaborated with esteemed colleagues such as Yoshiko Seto and Haruhisa Fujita. These partnerships have fostered a collaborative environment that enhances the research and development of innovative medical solutions.

Conclusion

Munemoto Itoh's contributions to the field of antimalignant agents highlight his role as a key innovator in medical science. His patent and ongoing work at Tobishi Pharmaceutical Co., Ltd. reflect his dedication to advancing cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…